Do Medibank shares now represent a buying opportunity?

Medibank has said it will not meet any ransom demands, which has seen the hackers begin to publish sensitive stolen customer data.

Key points
  • Medibank shares have fallen 21% since the company's October data breach
  • Stake reports its customers have seen this as a buying opportunity
  • At the current share price, the ASX 200 health insurer pays a trailing dividend yield of 4.8%

Medibank Private Ltd (ASX: MPL) shares have come under considerable selling pressure following the company's massive data breach last month.

On 26 October, when the S&P/ASX 200 Index (ASX: XJO) private health insurer emerged from a multi-day trading halt, shares plunged 18.1% over the day.

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

What's going on with the data breach?

In a nutshell, hackers — apparently Russian-based — stole sensitive data from 9.7 million of Medibank's former and current clients. That data includes customer names, dates of birth, addresses, phone numbers and email addresses.

The cybercriminals also accessed health claims data for approximately 480,000 customers.

Earlier this week, the healthcare stock said it would not cave into any ransom demands from the hackers, which saw Medibank shares rise on the day.

The hackers responded by threatening to publish all of the customer data on the dark web. A threat they began to follow through with yesterday.

Do Medibank shares now represent a buying opportunity?

Medibank shares remain down 21% since the company exited its trading halt on 26 October.

So, is it a buying opportunity?

Eliot Hastie, markets analyst at Australian brokerage platform Stake, said that for the platform's clients, the answer looks to be yes.

"Stake customers have seen this as a buying opportunity, with a 1,426% increase in buys last month, suggesting that many are still positive about Medibank's long-term outlook," he said. "In fact, Medibank saw the biggest change from sales to buys of all Australian stocks in October when compared to September."

According to Hastie:

Cyber security incidents often cause an instant hard shock to a share price, but strong companies have generally been able to recover over the long term. That said, there's no way of knowing the true consequences of Medibank's current breach.

There has been a suggestion of a class action lawsuit, which could affect the share price over a longer period, but this situation is still developing, and its impact is yet to be seen.

If you're considering investing in Medibank shares, there's also the potential income stream to keep in mind.

As at yesterday's closing share price of $2.77, Medibank pays a trailing dividend yield of 4.8%, fully franked.

How have Medibank shares been tracking in 2022?

The Medibank share price was in the green, significantly outperforming the ASX 200 over the calendar year, right up until the big selloff on 26 October. That selling now sees Medibank shares down 19% in 2022, compared to an 8% loss posted by the benchmark index.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three healthcare workers standing together and smiling.
Healthcare Shares

Pro Medicus signs A$24M US deal

Pro Medicus shares are in the spotlight after announcing a major US contract win for its Visage cloud imaging platform.

Read more »

Two pharmacist talking to each other.
Healthcare Shares

How much could the Sigma Healthcare share price rise in the next year?

Could this stock deliver healthy returns?

Read more »

A business man wearing a life jacket prepares to jump off a sinking boat
ASX Share Market News

ASX 200 utilities and healthcare shares win the week again

This is the second week in which these traditionally defensive market sectors outperformed.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »